

**Results** Among 700 patients randomized, 508 (73% of expected) and 432 (86% of expected) completed respectively baseline QOL and SHA. Compliance post-baseline was 56% to 69% for QOL and 63% to 79% for SHA with 58% of patients reporting QoL and 63% responding to the SHA at 36 months. Mean baseline scores were high for all EORTC QLQ-C30 functional scales. EORTC symptoms with the highest (worst) mean baseline scores were fatigue (24.5 on SH and 24.1 on RH) and sleep (29.9 on SH and 32.0 on RH). Mean baseline FSFI and FSDS-R total scores were respectively 27.1 and 10.9 on SH and 27.6 and 10.1 on RH; all were in the non-clinical range.. Significant differences in favor of treatment with SH was found for the following domains: EORTC QLQ-C30 pain scale; EORTC QLQ-CX24 symptom experiences, body image, sexual-vaginal functioning, and sexual worry, sexual activities, and sexual enjoyment scales; FSFI desire, arousal, lubrication, pain scales and total score; and FSDS-R total score.

**Conclusion** Better quality of life and sexual health were observed with SH compared to RH.

#630

# **LOWER-LIMB LYMPHEDEMA AFTER SENTINEL LYMPH NODE BIOPSY IN CERVICAL CANCER PATIENTS: FINAL RESULTS OF THE SENTIX PROSPECTIVE INTERNATIONAL STUDY (CEEGOG CX-01/ENGOT-CX2)**

<sup>1</sup>Christhardt Köhler\*, <sup>2</sup>David Cibula, <sup>3</sup>Martina Romanova, <sup>4</sup>Martina Borcinova, <sup>5</sup>Maria Letizia Di Meo, <sup>6</sup>Lus Van Lonkhuijzen, <sup>7</sup>Rene Laky, <sup>8</sup>Sergey Baydo, <sup>9</sup>Cristina Zorrero, <sup>10</sup>Mathieu Luyckx, <sup>11</sup>Marcin Misiak, <sup>12</sup>Pluvio J Coronado, <sup>13</sup>Maxime Fastrez, <sup>14</sup>Grzegorz Szwedczyk, <sup>15</sup>Barbara Kipp, <sup>16</sup>Sveig Tingulstad, <sup>17</sup>Javier De Santiago, <sup>18</sup>Robert Poka, <sup>1</sup>Andrea Plaikner, <sup>4</sup>Roman Kocian. <sup>1</sup>Asklepios-Clinic Hamburg Altona, Department of Gynaecology, Hamburg, Germany, Hamburg, Germany; <sup>2</sup>First Faculty of Medicine, Charles University and General University Hospital in Prague, Department of Obstetrics and Gynecology, Prague, Czech Republic, CEEGOG, Hamburg, Czech Republic; <sup>3</sup>University Hospital Ostrava, Department of Obstetrics and Gynecology, Ostrava, Czech Republic, CEEGOG, Ostrava, Czech Republic; <sup>4</sup>First Faculty of Medicine, Charles University and General University Hospital in Prague, Department of Obstetrics and Gynecology, Prague, Czech Republic, CEEGOG, Prague, Czech Republic; <sup>5</sup>San Gerardo Hospital, Department of Obstetrics and Gynecology, Unit of Gynecologic Oncology Surgery, Monza, Italy, Monza, Italy; <sup>6</sup>Amsterdam University Medical Centers, Center for Gynecologic Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands, Amsterdam, The Netherlands; <sup>7</sup>Medical University of Graz, University Hospital for Gynecology and Obstetrics, Department of Gynecology, Graz, Austria, Graz, Austria; <sup>8</sup>LISOD – Israeli Oncological Hospital, Plyuty, Ukraine, CEEGOG, Plyuty, Ukraine; <sup>9</sup>Instituto Valenciano de Oncología (IVO), Gynecology Department, Valencia, Spain, Valencia, Spain; <sup>10</sup>Cliniques universitaires Saint-Luc, Brussels, Belgium, BGOG, Brussels, Belgium; <sup>11</sup>Holycross Cancer Center, Department of Gynecologic Oncology Kielce, Poland, CEEGOG, Kielce, Poland; <sup>12</sup>Hospital Clinico San Carlos, Department of Gynecology and Obstetrics, Madrid, Spain, Madrid, Spain; <sup>13</sup>Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), CUB Erasme, Brussels, Belgium, BGOG, Brussels, Belgium; <sup>14</sup>Medical University of Warsaw, Department of Biophysics, Physiology and Pathophysiology; Department of Obstetrics, Perinatology and Gynecology, Warsaw, Poland, CEEGOG, Warsaw, Poland; <sup>15</sup>Cantonal Hospital of Lucerne, Department of Obstetrics and Gynecology, Lucerne, Switzerland, Lucerne, Switzerland; <sup>16</sup>St. Olav's University Hospital, Department of Gynaecology, Trondheim, Norway, Trondheim, Norway; <sup>17</sup>MD Anderson Cancer Center, Madrid, Spain, Madrid, Spain; <sup>18</sup>University of Debrecen, Faculty of Medicine, Department of Obstetrics and Gynecology, Debrecen, Hungary, CEEGOG, Debrecen, Hungary


10.1136/ijgc-2023-ESGO.47

**Introduction/Background** Background The sentinel lymph node (SLN) concept was developed with the purpose of alleviating postoperative morbidity, particularly lower limb lymphedema (LLL). We report the final analysis of the occurrence of LLL

after SLN biopsy or systematic pelvic lymph node dissection (PLND) in the prospective SENTIX study.

**Methodology** SENTIX was conducted at 47 sites in 18 countries. Patients with stages 1A1/LVSI+ to 1B2 (FIGO 2018), usual histological types, and no suspicious lymph nodes on imaging were prospectively enrolled between 05/2016 and 10/2020. All patients underwent SLN biopsy and hysterectomy/trachelectomy. Patients with unilaterally detected/undetected SLNs and those in whom the SLN was intraoperatively positive, underwent systematic PLND. LLL was assessed at 6-month intervals for the period of 2 years. The assessment was based on a persistent limb volume increase [LVI] calculated using serial limb circumference measurements.

**Results** Among 578 evaluable patients, 486 underwent SLN biopsy only and 92 underwent PLND. The cumulative incidence of LLL at 24 months in the SLN and PLND groups was 28.0% and 29.0% ( $p=0.900$ ). Persistent LVI >40% occurred at a similar frequency in both groups, with cumulative rates of 1.8% and 1.1% in the SLN and PLND groups, respectively ( $p=1.0$ ) (figure 1). Although we observed a tendency towards more frequent mild LLL in the SLN group, the difference was not statistically significant ( $p=0.256$ ). The median interval to LLL onset was 9 months in both groups. Transient oedema that resolved without intervention within 6 months was reported in an additional 15.2% and 13.0% of patients in the SLN and PLND groups, respectively.



**Abstract #630 Figure 1** Postoperative cumulative incidence of LLL in the SLN and PLND cohorts. LLL: limb lymphedema defined as a limb volume increase (LVI); black (LVI >40%); dark grey: moderate LLL (LVI 20–39%); light grey: mild LLL (LVI 10–19%)

**Conclusion** Severe persistent LLL occurred rarely after surgical pelvic LN staging in cervical cancer patients. Contrary to our expectations, de-escalation from systematic PLND to SLN biopsy was not associated with a significantly decreased risk of mild-to-moderate LLL.

## 11. Translational research/biomarkers

### #64 HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) TESTING ON CELL-FREE TUMOR DNA FROM PERITONEAL FLUID OF PATIENT WITH EPITHELIAL OVARIAN CANCER

Cyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, Damien Vasseur, Audrey Le Formal, Laure Chardin, Sebastien Gouy, Amandine Maulard, Stephanie Scherier, Claire Sanson, Ludovic Lacroix, Sophie Cotteret, Lea Mauny, Francois Zaccarini, Etienne Rouleau, Alexandra Leary\*. *Institut Gustave Roussy, Villejuif, France*

10.1136/ijgc-2023-ESGO.48

**Introduction/Background** Knowledge regarding homologous recombination deficiency (HRD) status at diagnosis is essential to manage patients with advanced epithelial ovarian cancer (EOC). These genomic tests are performed on tumor samples and unfortunately the analysis of tumor DNA are missing 15–19% of cases.

**Methodology** We collected ascites or peritoneal washings (20ml) from 53 patients undergoing primary or secondary laparoscopy for suspicion of EOC, or therapeutic paracentesis. A Cancer Gene Panel (CGP) was analyzed by Next generation sequencing (NGS) for TP53 genes and HR genes and shallow Whole Genome Sequencing (sWGS) was used to measure genomic instability on cftDNA from peritoneal fluid

**Results** A total of 53 patients were included. Cell-free DNA (cfDNA) was detectable in 49/53 patients (92,5%) even when there was little peritoneal fluid (<100cc) at laparoscopy (n=7). Median cfDNA extracted from 20ml peritoneal fluid or washings was high at 3700 ng/ml (range 109 – 65 000 ng/ml) and median turn-around testing time was 21 days. 42 patients (86%) had a TP53 pathogenic variant, all cases were HGSOC. Seven (14%) and 5 (10%) had a BRCA1 or BRCA2 pathogenic variant, respectively. The sensitivity, specificity and concordance of acfDNA compared with tumor testing for TP53 pathogenic variant detection were 97% (95% IC : 86%-100%), 83% (95% IC : 43%-100%) and 95% (K = 0,81: P <0,001) respectively. NGS CGP on cftDNA was contributive in 5 patients with failed NGS CGP on tumor DNA from tissue, including one patient with a BRCA2 pathogenic variant identified in cftDNA. Genomic instability was assessed by sWGS on cftDNA and provided a contributive result for all samples tested, including 7 for which matching tissue-based GIS testing failed.

**Conclusion** Genomic profiling on cftDNA from peritoneal fluid is feasible and yields high quantity of tumor DNA. HRD testing on cfDNA from peritoneal fluid should be proposed to every patient undergoing primary laparoscopy.

**Disclosures** Work supported by donations from patients and families through the 'Parrainage Cancers Gynécologiques' program

### #71 INTEGRATED MULTI-OMIC AND CLINICOPATHOLOGICAL ANALYSIS OF HIGH-GRADE SEROUS OVARIAN CANCER IN BRCA1/2 MUTATED PATIENTS WITH POOR SURVIVAL: IDENTIFICATION OF PREDICTIVE BIOMARKERS FOR PERSONALIZED TREATMENT

<sup>1,2</sup>Tibor A Zwimpfer\*, <sup>1,3</sup>Sian Fereday, <sup>1</sup>Ahwan Pandey, <sup>1</sup>Laura Twomey, <sup>1</sup>Dinuka Ariyaratne, <sup>4</sup>Ellen L Goode, <sup>5,6,7</sup>Brad H Nelson, <sup>8,9,10</sup>Anna Defazio, <sup>1,3</sup>David DL Bowtell, <sup>1,3</sup>Dale W Garsed. <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, Australia; <sup>2</sup>University Hospital Basel, Department of Gynaecological Oncology, Basel, Switzerland; <sup>3</sup>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; <sup>4</sup>Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA; <sup>5</sup>The Deeley Research Centre, BC Cancer, Victoria, Canada; <sup>6</sup>Department of Medical Genetics, The University of British Columbia, Vancouver, Canada; <sup>7</sup>Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada; <sup>8</sup>The Westmead Institute for Medical Research, Sydney, Australia; <sup>9</sup>Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia; <sup>10</sup>The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia

10.1136/ijgc-2023-ESGO.49

**Introduction/Background** Pathogenic germline BRCA1/2 alterations (gBRCA) are common in patients with high-grade serous ovarian carcinoma (HGSOC) and are generally associated with better chemotherapy response and longer 5-year-survival. However, fewer gBRCA1-carriers are alive at 10 years compared to non-carriers and gBRCA2-carriers. Clinicopathological and multi-omic features of HGSOC were compared in BRCA1/2-mutated patients with short and long-term survival to identify factors influencing clinical outcomes.

**Methodology** Whole-genome-sequencing, RNA-sequencing and clinicopathological analysis on primary HGSOC tumors from 35 advanced-stage BRCA1/2-mutant with short survival (≤3-years) was compared with data from 84 patients with >3-year survival (44 BRCA-mutant, 40 BRCA-wildtype), and 35 BRCA-wildtype patients with short survival. We also assessed clinicopathological features and tumor immune markers by multiplexed immunofluorescence in 293 and 146 gBRCA-carriers, respectively.

**Results** Prognostic features including residual disease, age, grade, FIGO stage, primary site, and BRCA type (BRCA1 vs BRCA2) could not explain short survival in BRCA-mutants relative to those with longer survival. Somatic mutation and neoantigen burden were equivalent between the two survival groups of BRCA-mutants, however the homologous recombination DNA repair deficiency (HRD) score was significantly higher in BRCA-mutants with long survival compared to those with short survival (73.6 vs 65.5, p=0.007). T-cell (PD1+,CD4+) density was associated with good outcomes in BRCA-mutants (p=0.003). Mutational signature clustering identified a group of BRCA-mutants characterised by short survival, low HRD-scores, and DNA copy number signature CN9 which is associated with increased leucocyte fraction and poor disease-specific survival. PIK3CA alterations were enriched in BRCA2-mutants with short survival (5/10, 50%, p=0.061).

**Conclusion** Survival in BRCA-mutants with HGSOC was associated with distinct mutational signatures, differential immune responses, somatic gene alterations, and differences in the extent of HRD. Integration of multi-omic data with clinical variables can enhance the accuracy of predictive models and